Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain.

Grunewald, Susanne; Klug, Lillian R; Muhlenberg, Thomas; Lategahn, Jonas; Falkenhorst, Johanna; Town, Ajia; Ehrt, Christiane; Wardelmann, Eva; Hartmann, Wolfgang; Schildhaus, Hans-Ulrich; Treckmann, Juergen; Fletcher, Jonathan A; Jung, Sascha; Czodrowski, Paul; Miller, Stephen; Schmidt-Kittler, Oleg; Rauh, Daniel; Heinrich, Michael C; Bauer, Sebastian

Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib with the notable exception of the most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. Tumor and plasma biopsies in 6 of 7 patients with PDGFRA primary mutations who progressed on avapritinib or imatinib had secondary resistance mutations within PDGFRA exons 13, 14 and 15 that interfere with avapritinib binding. Secondary PDGFRA mutations causing V658A, N659K, Y676C, and G680R substitutions were found in 2 or more patients each, representing recurrent mechanisms of PDGFRA GIST drug resistance. Notably, most PDGFRA-mutant GIST refractory to avapritinib remain dependent on the PDGFRA oncogenic signal. Inhibitors that target PDGFRA protein stability or inhibition of PDGFRA-dependent signaling pathways may overcome avapritinib resistance.